Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of VX-135 in combination with daclatasvir for genotype 1 chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• VX-135

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Chronic Hepatitis C, CHC | Phase 2 | Status: COMPLETED